Peripheral effects Via the AMY2 and AMY3 receptors Cagrilintide acts peripherally: Slowing of gastric emptying , stronger than with GLP-1 Suppression of postprandial glucagon , helps control postprandial glycemic spikes Modulation of bone remodeling (via AMY3), a neutral effect, but clinically monitored Synergy with GLP-1 (the mechanistic basis of CagriSema) The main innovation is the complementarity with the GLP-1 pathway : GLP-1 suppresses appetite via the arcuate nucleus of the hypothalamus (POMC neurons, AgRP/NPY inhibition) Amylin suppresses appetite via the area postrema (CGRP-like neurons) Two independent centers, two independent mechanisms
PMID: 18856211
it distributes through your whole system regardless
Providers monitor: Tolerance and side effects Weight loss progress Overall health response Tirzepatide vs Other GLP-1 Medications Compared to semaglutide-based medications, tirzepatide targets two hormone pathways (GLP-1 and GIP), which may provide additional metabolic support for some patients
Conclusion The peptide research most relevant to gut health centers on BPC-157 for mucosal repair and intestinal lining integrity, KPV for targeted intestinal anti-inflammatory signaling, and GHK-Cu for broader tissue repair support
During the early post-operative weeks, when patients progress through liquid and pure stages, potassium intake can be particularly restricted